Amantadine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amantadine" in English language version.

refsWebsite

Global rank English rank

79nih.gov

4^th place

50doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

5web.archive.org

1^st place

4fda.gov

447^th place

338^th place

3cdc.gov

218^th place

212^th place

3harvard.edu

18^th place

17^th place

3drugs.com

399^th place

333^rd place

2handle.net

102^nd place

76^th place

1tga.gov.au

3,984^th place

2,622^nd place

1in.gov.br

3,151^st place

5,932^nd place

1medicines.org.uk

3,823^rd place

2,387^th place

1who.int

195^th place

302^nd place

1worldcat.org

5^th place

1karger.com

4,489^th place

4,454^th place

1nice.org.uk

3,258^th place

2,666^th place

1symmetrel.com

low place

1springer.com

274^th place

309^th place

1medsafe.govt.nz

low place

1drugbank.ca

4,294^th place

6,357^th place

1ebi.ac.uk

5,849^th place

7,886^th place

1books.google.com

3^rd place

1nytimes.com

7^th place

1medlineplus.gov

1,581^st place

1,299^th place

1washingtonpost.com

34^th place

27^th place

1medpress.com.pl

low place

books.google.com

Hounshell DA, Smith JK (1988). Science and Corporate Strategy: Du Pont R&D, 1902–1980 John. Cambridge University Press. p. 469. ISBN 978-0521327671.

cdc.gov

"Influenza Antiviral Medications: Summary for Clinicians". U.S. Centers for Disease Control and Prevention (CDC). 17 April 2019. Retrieved 14 July 2019.
"Seasonal Influenza (Flu) – Weekly Report: Influenza Summary Update". U.S. Centers for Disease Control and Prevention (CDC). 5 September 2009.
"Antiviral Drug Resistance among Influenza Viruses". U.S. Centers for Disease Control and Prevention (CDC). 17 April 2019. Retrieved 11 November 2020.

doi.org

Danysz W, Dekundy A, Scheschonka A, Riederer P (February 2021). "Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials". J Neural Transm (Vienna). 128 (2): 127–169. doi:10.1007/s00702-021-02306-2. PMC 7901515. PMID 33624170.
Huber TJ, Dietrich DE, Emrich HM (March 1999). "Possible use of amantadine in depression". Pharmacopsychiatry. 32 (2): 47–55. doi:10.1055/s-2007-979191. PMID 10333162.
James SH, Whitley RJ (2017). "Influenza Viruses". Infectious Diseases. Elsevier. pp. 1465–1471.e1. doi:10.1016/b978-0-7020-6285-8.00172-6. ISBN 978-0-7020-6285-8.
Balgi AD, Wang J, Cheng DY, Ma C, Pfeifer TA, Shimizu Y, et al. (1 February 2013). Bouvier NM (ed.). "Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay". PLOS ONE. 8 (2): e55271. Bibcode:2013PLoSO...855271B. doi:10.1371/journal.pone.0055271. PMC 3562233. PMID 23383318.
Ragshaniya A, Kumar V, Tittal RK, Lal K (March 2024). "Nascent pharmacological advancement in adamantane derivatives". Arch Pharm (Weinheim). 357 (3): e2300595. doi:10.1002/ardp.202300595. PMID 38128028.
Hubsher G, Haider M, Okun MS (April 2012). "Amantadine: the journey from fighting flu to treating Parkinson disease". Neurology. 78 (14): 1096–9. doi:10.1212/WNL.0b013e31824e8f0d. PMID 22474298. S2CID 21515610.
Hauser RA, Lytle J, Formella AE, Tanner CM (March 2022). "Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease". npj Parkinson's Disease. 8 (1): 29. doi:10.1038/s41531-022-00291-1. PMC 8933492. PMID 35304480.
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R (2018). "Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials". Braz J Psychiatry. 40 (4): 449–458. doi:10.1590/1516-4446-2017-2393. PMC 6899375. PMID 29898194.
Rascol O, Fabbri M, Poewe W (December 2021). "Amantadine in the treatment of Parkinson's disease and other movement disorders". The Lancet. Neurology. 20 (12): 1048–1056. doi:10.1016/s1474-4422(21)00249-0. PMID 34678171. S2CID 239031883.
Crosby NJ, Deane KH, Clarke CE, et al. (Cochrane Movement Disorders Group) (22 April 2003). "Amantadine for dyskinesia in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2010 (2): CD003467. doi:10.1002/14651858.CD003467. PMC 8715285. PMID 12804468.
Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ, et al. (Cochrane Acute Respiratory Infections Group) (November 2014). "Amantadine and rimantadine for influenza A in children and the elderly". The Cochrane Database of Systematic Reviews. 2014 (11): CD002745. doi:10.1002/14651858.CD002745.pub4. PMC 7093890. PMID 25415374.
Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C, et al. (Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group) (January 2007). "Amantadine for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2007 (1): CD002818. doi:10.1002/14651858.CD002818.pub2. PMC 6991937. PMID 17253480.
Payne C, Wiffen PJ, Martin S (April 2017). "WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness". The Cochrane Database of Systematic Reviews. 4 (4). Chichester, UK: John Wiley & Sons, Ltd: CD008427. doi:10.1002/14651858.cd008427. PMC 6478103. PMID 28387447.
Generali JA, Cada DJ (September 2014). "Amantadine: multiple sclerosis-related fatigue". Hospital Pharmacy. 49 (8): 710–2. doi:10.1310/hpj4908-710. PMC 4252198. PMID 25477595.
Henze T, Rieckmann P, Toyka KV (2006). "Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society". European Neurology. 56 (2): 78–105. doi:10.1159/000095699. PMID 16966832. S2CID 5069086.
Ma HM, Zafonte RD (February 2020). "Amantadine and memantine: a comprehensive review for acquired brain injury". Brain Injury. 34 (3): 299–315. doi:10.1080/02699052.2020.1723697. PMID 32078407. S2CID 211232548.
Gao Y, Ma L, Liang F, Zhang Y, Yang L, Liu X, et al. (July 2020). "The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage". Brain Injury. 34 (8): 1084–1088. doi:10.1080/02699052.2020.1780315. PMID 32552090. S2CID 219909194.
Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. (September 2018). "Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research". Neurology. 91 (10): 450–460. doi:10.1212/WNL.0000000000005926. PMC 6139814. PMID 30089618.
Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. (March 2012). "Placebo-controlled trial of amantadine for severe traumatic brain injury". The New England Journal of Medicine. 366 (9): 819–26. doi:10.1056/NEJMoa1102609. PMID 22375973.
Bahrani E, Nunneley CE, Hsu S, Kass JS (March 2016). "Cutaneous Adverse Effects of Neurologic Medications". CNS Drugs. 30 (3): 245–67. doi:10.1007/s40263-016-0318-7. PMID 26914914. S2CID 10560952.
Vollum DI, Parkes JD, Doyle D (June 1971). "Livedo reticularis during amantadine treatment". British Medical Journal. 2 (5762): 627–8. doi:10.1136/bmj.2.5762.627. PMC 1796527. PMID 5580722.
Tarsy D, Parkes JD, Marsden CD (April 1975). "Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias". Journal of Neurology, Neurosurgery, and Psychiatry. 38 (4): 331–335. doi:10.1136/jnnp.38.4.331. PMC 491929. PMID 1095689.
Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (April 1991). "Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study". European Journal of Pharmacology. 206 (4): 297–300. doi:10.1016/0922-4106(91)90113-v. PMID 1717296.
Blanpied TA, Clarke RJ, Johnson JW (March 2005). "Amantadine inhibits NMDA receptors by accelerating channel closure during channel block". The Journal of Neuroscience. 25 (13): 3312–22. doi:10.1523/JNEUROSCI.4262-04.2005. PMC 6724906. PMID 15800186.
Kornhuber J, Schoppmeyer K, Riederer P (December 1993). "Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex". Neurosci Lett. 163 (2): 129–131. doi:10.1016/0304-3940(93)90362-o. PMID 8309617.
Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (April 2004). "Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine". The European Journal of Neuroscience. 19 (8): 2212–20. doi:10.1111/j.0953-816X.2004.03297.x. PMID 15090047. S2CID 19479968.
Strömberg U, Svensson TH (November 1971). "Further studies on the mode of action of amantadine". Acta Pharmacologica et Toxicologica. 30 (3): 161–71. doi:10.1111/j.1600-0773.1971.tb00646.x. PMID 5171936.
Shimazu S, Takahata K, Katsuki H, Tsunekawa H, Tanigawa A, Yoneda F, et al. (June 2001). "(-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release". Eur J Pharmacol. 421 (3): 181–189. doi:10.1016/s0014-2999(01)01040-8. PMID 11516435.
Yoneda F, Moto T, Sakae M, Ohde H, Knoll B, Miklya I, et al. (May 2001). "Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Bioorg Med Chem. 9 (5): 1197–1212. doi:10.1016/s0968-0896(01)00002-5. PMID 11377178.
Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I (December 1999). "(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Br J Pharmacol. 128 (8): 1723–1732. doi:10.1038/sj.bjp.0702995. PMC 1571822. PMID 10588928.
Thomaston JL, Alfonso-Prieto M, Woldeyes RA, Fraser JS, Klein ML, Fiorin G, et al. (November 2015). "High-resolution structures of the M2 channel from influenza A virus reveal dynamic pathways for proton stabilization and transduction". Proceedings of the National Academy of Sciences of the United States of America. 112 (46): 14260–5. Bibcode:2015PNAS..11214260T. doi:10.1073/pnas.1518493112. PMC 4655559. PMID 26578770.
Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M (20 April 2017). "Drug resistance in influenza A virus: the epidemiology and management". Infection and Drug Resistance. 10: 121–134. doi:10.2147/idr.s105473. PMC 5404498. PMID 28458567.
Deleu D, Northway MG, Hanssens Y (2002). "Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease". Clinical Pharmacokinetics. 41 (4): 261–309. doi:10.2165/00003088-200241040-00003. PMID 11978145. S2CID 39359348.
Maugh TH (November 1979). "Panel urges wide use of antiviral drug". Science. 206 (4422): 1058–60. Bibcode:1979Sci...206.1058M. doi:10.1126/science.386515. PMID 386515.
Maugh TH (April 1976). "Amantadine: an alternative for prevention of influenza". Science. 192 (4235): 130–1. doi:10.1126/science.192.4235.130. PMID 17792438.
"International Review of Neurobiology", Recent advances in the use of Drosophila in neurobiology and neurodegeneration, International Review of Neurobiology, vol. 99, Elsevier, 2011, pp. i–iii, doi:10.1016/b978-0-12-387003-2.00010-0, ISBN 978-0-12-387003-2, retrieved 11 November 2020
Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA, Sanicas M (April 2018). "The emerging influenza virus threat: status and new prospects for its therapy and control". Archives of Virology. 163 (4): 831–844. doi:10.1007/s00705-018-3708-y. PMC 7087104. PMID 29322273.
Schwab RS, England AC, Poskanzer DC, Young RR (May 1969). "Amantadine in the treatment of Parkinson's disease". JAMA. 208 (7): 1168–1170. doi:10.1001/jama.1969.03160070046011. PMID 5818715.
Schwab RS, Poskanzer DC, England AC, Young RR (November 1972). "Amantadine in Parkinson's disease. Review of more than two years' experience". JAMA. 222 (7): 792–5. doi:10.1001/jama.222.7.792. PMID 4677928.
Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Test Anal. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID 24678061.
Heal DJ, Gosden J, Smith SL (November 2018). "Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans". Neuropharmacology. 142: 89–115. doi:10.1016/j.neuropharm.2018.01.049. PMID 29427652.
Aoki FY, Boivin G, Roberts N (2007). "Influenza virus susceptibility and resistance to oseltamivir". Antiviral Therapy. 12 (4 Pt B): 603–16. doi:10.1177/135965350701200S04.1. PMID 17944268. S2CID 25907483.
Deutschenbaur L, Beck J, Kiyhankhadiv A, Mühlhauser M, Borgwardt S, Walter M, et al. (January 2016). "Role of calcium, glutamate and NMDA in major depression and therapeutic application". Prog Neuropsychopharmacol Biol Psychiatry. 64: 325–33. doi:10.1016/j.pnpbp.2015.02.015. PMID 25747801.
Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S (July 2022). "Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials". Iran J Psychiatry. 17 (3): 320–340. doi:10.18502/ijps.v17i3.9733. PMC 9699814. PMID 36474699.
Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". Eur Neuropsychopharmacol. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897.
Pozzi M, Bertella S, Gatti E, Peeters GG, Carnovale C, Zambrano S, et al. (December 2020). "Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)". Expert Opin Emerg Drugs. 25 (4): 395–407. doi:10.1080/14728214.2020.1820481. hdl:2434/851076. PMID 32938246.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S (November 2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology. 25 (7–8): 560–565. doi:10.1002/hup.1154. PMID 21312290. S2CID 30677758.
Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA (September 2021). "Amantadine for the treatment of childhood and adolescent psychiatric symptoms". Proceedings. 34 (5): 566–570. doi:10.1080/08998280.2021.1925827. PMC 8366930. PMID 34456474.
Marinescu I, Marinescu D, Mogoantă L, Efrem IC, Stovicek PO (2020). "SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine". Rom J Morphol Embryol. 61 (4): 1007–1022. doi:10.47162/RJME.61.4.03. PMC 8343601. PMID 34171050.

dx.doi.org

"International Review of Neurobiology", Recent advances in the use of Drosophila in neurobiology and neurodegeneration, International Review of Neurobiology, vol. 99, Elsevier, 2011, pp. i–iii, doi:10.1016/b978-0-12-387003-2.00010-0, ISBN 978-0-12-387003-2, retrieved 11 November 2020

drugbank.ca

"Amantadine". drugbank.ca. Retrieved 13 July 2019.

drugs.com

"Amantadine Hydrochloride Monograph for Professionals". Drugs.com. Retrieved 16 November 2020.
"Amantadine – FDA prescribing information, side effects and uses". Drugs.com. Retrieved 16 November 2020.
"Amantadine (International database)". Drugs.com. 5 August 2024. Retrieved 12 August 2024.

ebi.ac.uk

"Rimantadine hydrochloride (CHEBI:8865)". ebi.ac.uk. Retrieved 13 July 2019.

fda.gov

accessdata.fda.gov

"Symmetrel (Amantadine Hydrochloride, USP) fact sheet" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 28 July 2019.
Bastings E. "NDA 208944 Approval Letter" (PDF).
"Drug Approval Package: Gocovri (amantadine extended-release)". U.S. Food and Drug Administration (FDA). 29 June 2018. Retrieved 22 January 2020.
"Enforcement Report – Week of September 23, 2015". U.S. Food and Drug Administration (FDA). Archived from the original on 2 October 2015. Retrieved 30 September 2015.

handle.net

hdl.handle.net

Stuart MC, Kouimtzi M, Hill SR, eds. (2009). WHO Model Formulary 2008. World Health Organization (WHO). p. 242. hdl:10665/44053. ISBN 978-9241547659.
Pozzi M, Bertella S, Gatti E, Peeters GG, Carnovale C, Zambrano S, et al. (December 2020). "Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)". Expert Opin Emerg Drugs. 25 (4): 395–407. doi:10.1080/14728214.2020.1820481. hdl:2434/851076. PMID 32938246.

harvard.edu

ui.adsabs.harvard.edu

Balgi AD, Wang J, Cheng DY, Ma C, Pfeifer TA, Shimizu Y, et al. (1 February 2013). Bouvier NM (ed.). "Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay". PLOS ONE. 8 (2): e55271. Bibcode:2013PLoSO...855271B. doi:10.1371/journal.pone.0055271. PMC 3562233. PMID 23383318.
Thomaston JL, Alfonso-Prieto M, Woldeyes RA, Fraser JS, Klein ML, Fiorin G, et al. (November 2015). "High-resolution structures of the M2 channel from influenza A virus reveal dynamic pathways for proton stabilization and transduction". Proceedings of the National Academy of Sciences of the United States of America. 112 (46): 14260–5. Bibcode:2015PNAS..11214260T. doi:10.1073/pnas.1518493112. PMC 4655559. PMID 26578770.
Maugh TH (November 1979). "Panel urges wide use of antiviral drug". Science. 206 (4422): 1058–60. Bibcode:1979Sci...206.1058M. doi:10.1126/science.386515. PMID 386515.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

karger.com

Henze T, Rieckmann P, Toyka KV (2006). "Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society". European Neurology. 56 (2): 78–105. doi:10.1159/000095699. PMID 16966832. S2CID 5069086.

medicines.org.uk

"Trilasym 50 mg/ 5 ml Oral Solution – Summary of Product Characteristics (SmPC)". (emc). 24 September 2019. Archived from the original on 26 March 2020. Retrieved 26 March 2020.

medlineplus.gov

"Amantadine: MedlinePlus Drug Information". medlineplus.gov. Retrieved 22 July 2019.

medpress.com.pl

Płusa T (February 2021). "Przeciwzapalne działanie amantadyny i memantyny w zakażeniu SARS-CoV-2" [Anti-inflammatory effects of amantadine and memantine in SARS-CoV-2 infection]. Pol Merkur Lekarski (in Polish). 49 (289): 67–70. PMID 33713098.

medsafe.govt.nz

"Some medicines increase serum creatinine without affecting glomerular function".

nice.org.uk

"Recommendations | Multiple sclerosis in adults: Management | Guidance | NICE". 22 June 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chang C, Ramphul K (2020). "Amantadine". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29763128. Retrieved 2 November 2020.
Danysz W, Dekundy A, Scheschonka A, Riederer P (February 2021). "Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials". J Neural Transm (Vienna). 128 (2): 127–169. doi:10.1007/s00702-021-02306-2. PMC 7901515. PMID 33624170.
Huber TJ, Dietrich DE, Emrich HM (March 1999). "Possible use of amantadine in depression". Pharmacopsychiatry. 32 (2): 47–55. doi:10.1055/s-2007-979191. PMID 10333162.
Balgi AD, Wang J, Cheng DY, Ma C, Pfeifer TA, Shimizu Y, et al. (1 February 2013). Bouvier NM (ed.). "Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay". PLOS ONE. 8 (2): e55271. Bibcode:2013PLoSO...855271B. doi:10.1371/journal.pone.0055271. PMC 3562233. PMID 23383318.
Ragshaniya A, Kumar V, Tittal RK, Lal K (March 2024). "Nascent pharmacological advancement in adamantane derivatives". Arch Pharm (Weinheim). 357 (3): e2300595. doi:10.1002/ardp.202300595. PMID 38128028.
Hubsher G, Haider M, Okun MS (April 2012). "Amantadine: the journey from fighting flu to treating Parkinson disease". Neurology. 78 (14): 1096–9. doi:10.1212/WNL.0b013e31824e8f0d. PMID 22474298. S2CID 21515610.
Hauser RA, Lytle J, Formella AE, Tanner CM (March 2022). "Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease". npj Parkinson's Disease. 8 (1): 29. doi:10.1038/s41531-022-00291-1. PMC 8933492. PMID 35304480.
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R (2018). "Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials". Braz J Psychiatry. 40 (4): 449–458. doi:10.1590/1516-4446-2017-2393. PMC 6899375. PMID 29898194.
Rascol O, Fabbri M, Poewe W (December 2021). "Amantadine in the treatment of Parkinson's disease and other movement disorders". The Lancet. Neurology. 20 (12): 1048–1056. doi:10.1016/s1474-4422(21)00249-0. PMID 34678171. S2CID 239031883.
Crosby NJ, Deane KH, Clarke CE, et al. (Cochrane Movement Disorders Group) (22 April 2003). "Amantadine for dyskinesia in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2010 (2): CD003467. doi:10.1002/14651858.CD003467. PMC 8715285. PMID 12804468.
Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ, et al. (Cochrane Acute Respiratory Infections Group) (November 2014). "Amantadine and rimantadine for influenza A in children and the elderly". The Cochrane Database of Systematic Reviews. 2014 (11): CD002745. doi:10.1002/14651858.CD002745.pub4. PMC 7093890. PMID 25415374.
Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C, et al. (Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group) (January 2007). "Amantadine for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2007 (1): CD002818. doi:10.1002/14651858.CD002818.pub2. PMC 6991937. PMID 17253480.
Payne C, Wiffen PJ, Martin S (April 2017). "WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness". The Cochrane Database of Systematic Reviews. 4 (4). Chichester, UK: John Wiley & Sons, Ltd: CD008427. doi:10.1002/14651858.cd008427. PMC 6478103. PMID 28387447.
Generali JA, Cada DJ (September 2014). "Amantadine: multiple sclerosis-related fatigue". Hospital Pharmacy. 49 (8): 710–2. doi:10.1310/hpj4908-710. PMC 4252198. PMID 25477595.
Henze T, Rieckmann P, Toyka KV (2006). "Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society". European Neurology. 56 (2): 78–105. doi:10.1159/000095699. PMID 16966832. S2CID 5069086.
Ma HM, Zafonte RD (February 2020). "Amantadine and memantine: a comprehensive review for acquired brain injury". Brain Injury. 34 (3): 299–315. doi:10.1080/02699052.2020.1723697. PMID 32078407. S2CID 211232548.
Gao Y, Ma L, Liang F, Zhang Y, Yang L, Liu X, et al. (July 2020). "The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage". Brain Injury. 34 (8): 1084–1088. doi:10.1080/02699052.2020.1780315. PMID 32552090. S2CID 219909194.
Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. (September 2018). "Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research". Neurology. 91 (10): 450–460. doi:10.1212/WNL.0000000000005926. PMC 6139814. PMID 30089618.
Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. (March 2012). "Placebo-controlled trial of amantadine for severe traumatic brain injury". The New England Journal of Medicine. 366 (9): 819–26. doi:10.1056/NEJMoa1102609. PMID 22375973.
Kafi H, Salamzadeh J, Beladimoghadam N, Sistanizad M, Kouchek M (2014). "Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke". Iranian Journal of Pharmaceutical Research. 13 (2): 591–8. PMC 4157035. PMID 25237355.
Hosenbocus S, Chahal R (February 2013). "Amantadine: a review of use in child and adolescent psychiatry". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 22 (1): 55–60. PMC 3565716. PMID 23390434.
Bahrani E, Nunneley CE, Hsu S, Kass JS (March 2016). "Cutaneous Adverse Effects of Neurologic Medications". CNS Drugs. 30 (3): 245–67. doi:10.1007/s40263-016-0318-7. PMID 26914914. S2CID 10560952.
Vollum DI, Parkes JD, Doyle D (June 1971). "Livedo reticularis during amantadine treatment". British Medical Journal. 2 (5762): 627–8. doi:10.1136/bmj.2.5762.627. PMC 1796527. PMID 5580722.
Tarsy D, Parkes JD, Marsden CD (April 1975). "Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias". Journal of Neurology, Neurosurgery, and Psychiatry. 38 (4): 331–335. doi:10.1136/jnnp.38.4.331. PMC 491929. PMID 1095689.
Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (April 1991). "Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study". European Journal of Pharmacology. 206 (4): 297–300. doi:10.1016/0922-4106(91)90113-v. PMID 1717296.
Blanpied TA, Clarke RJ, Johnson JW (March 2005). "Amantadine inhibits NMDA receptors by accelerating channel closure during channel block". The Journal of Neuroscience. 25 (13): 3312–22. doi:10.1523/JNEUROSCI.4262-04.2005. PMC 6724906. PMID 15800186.
Kornhuber J, Schoppmeyer K, Riederer P (December 1993). "Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex". Neurosci Lett. 163 (2): 129–131. doi:10.1016/0304-3940(93)90362-o. PMID 8309617.
Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (April 2004). "Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine". The European Journal of Neuroscience. 19 (8): 2212–20. doi:10.1111/j.0953-816X.2004.03297.x. PMID 15090047. S2CID 19479968.
Strömberg U, Svensson TH (November 1971). "Further studies on the mode of action of amantadine". Acta Pharmacologica et Toxicologica. 30 (3): 161–71. doi:10.1111/j.1600-0773.1971.tb00646.x. PMID 5171936.
Shimazu S, Takahata K, Katsuki H, Tsunekawa H, Tanigawa A, Yoneda F, et al. (June 2001). "(-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release". Eur J Pharmacol. 421 (3): 181–189. doi:10.1016/s0014-2999(01)01040-8. PMID 11516435.
Yoneda F, Moto T, Sakae M, Ohde H, Knoll B, Miklya I, et al. (May 2001). "Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Bioorg Med Chem. 9 (5): 1197–1212. doi:10.1016/s0968-0896(01)00002-5. PMID 11377178.
Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I (December 1999). "(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Br J Pharmacol. 128 (8): 1723–1732. doi:10.1038/sj.bjp.0702995. PMC 1571822. PMID 10588928.
Thomaston JL, Alfonso-Prieto M, Woldeyes RA, Fraser JS, Klein ML, Fiorin G, et al. (November 2015). "High-resolution structures of the M2 channel from influenza A virus reveal dynamic pathways for proton stabilization and transduction". Proceedings of the National Academy of Sciences of the United States of America. 112 (46): 14260–5. Bibcode:2015PNAS..11214260T. doi:10.1073/pnas.1518493112. PMC 4655559. PMID 26578770.
Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M (20 April 2017). "Drug resistance in influenza A virus: the epidemiology and management". Infection and Drug Resistance. 10: 121–134. doi:10.2147/idr.s105473. PMC 5404498. PMID 28458567.
Deleu D, Northway MG, Hanssens Y (2002). "Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease". Clinical Pharmacokinetics. 41 (4): 261–309. doi:10.2165/00003088-200241040-00003. PMID 11978145. S2CID 39359348.
Maugh TH (November 1979). "Panel urges wide use of antiviral drug". Science. 206 (4422): 1058–60. Bibcode:1979Sci...206.1058M. doi:10.1126/science.386515. PMID 386515.
Maugh TH (April 1976). "Amantadine: an alternative for prevention of influenza". Science. 192 (4235): 130–1. doi:10.1126/science.192.4235.130. PMID 17792438.
Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA, Sanicas M (April 2018). "The emerging influenza virus threat: status and new prospects for its therapy and control". Archives of Virology. 163 (4): 831–844. doi:10.1007/s00705-018-3708-y. PMC 7087104. PMID 29322273.
Schwab RS, England AC, Poskanzer DC, Young RR (May 1969). "Amantadine in the treatment of Parkinson's disease". JAMA. 208 (7): 1168–1170. doi:10.1001/jama.1969.03160070046011. PMID 5818715.
Schwab RS, Poskanzer DC, England AC, Young RR (November 1972). "Amantadine in Parkinson's disease. Review of more than two years' experience". JAMA. 222 (7): 792–5. doi:10.1001/jama.222.7.792. PMID 4677928.
Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Test Anal. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID 24678061.
Heal DJ, Gosden J, Smith SL (November 2018). "Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans". Neuropharmacology. 142: 89–115. doi:10.1016/j.neuropharm.2018.01.049. PMID 29427652.
Nicholson KL, Jones HE, Balster RL (May 1998). "Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine". Behav Pharmacol. 9 (3): 231–243. PMID 9832937.
Aoki FY, Boivin G, Roberts N (2007). "Influenza virus susceptibility and resistance to oseltamivir". Antiviral Therapy. 12 (4 Pt B): 603–16. doi:10.1177/135965350701200S04.1. PMID 17944268. S2CID 25907483.
Deutschenbaur L, Beck J, Kiyhankhadiv A, Mühlhauser M, Borgwardt S, Walter M, et al. (January 2016). "Role of calcium, glutamate and NMDA in major depression and therapeutic application". Prog Neuropsychopharmacol Biol Psychiatry. 64: 325–33. doi:10.1016/j.pnpbp.2015.02.015. PMID 25747801.
Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S (July 2022). "Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials". Iran J Psychiatry. 17 (3): 320–340. doi:10.18502/ijps.v17i3.9733. PMC 9699814. PMID 36474699.
Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". Eur Neuropsychopharmacol. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897.
Pozzi M, Bertella S, Gatti E, Peeters GG, Carnovale C, Zambrano S, et al. (December 2020). "Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)". Expert Opin Emerg Drugs. 25 (4): 395–407. doi:10.1080/14728214.2020.1820481. hdl:2434/851076. PMID 32938246.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S (November 2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology. 25 (7–8): 560–565. doi:10.1002/hup.1154. PMID 21312290. S2CID 30677758.
Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA (September 2021). "Amantadine for the treatment of childhood and adolescent psychiatric symptoms". Proceedings. 34 (5): 566–570. doi:10.1080/08998280.2021.1925827. PMC 8366930. PMID 34456474.
Płusa T (February 2021). "Przeciwzapalne działanie amantadyny i memantyny w zakażeniu SARS-CoV-2" [Anti-inflammatory effects of amantadine and memantine in SARS-CoV-2 infection]. Pol Merkur Lekarski (in Polish). 49 (289): 67–70. PMID 33713098.
Marinescu I, Marinescu D, Mogoantă L, Efrem IC, Stovicek PO (2020). "SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine". Rom J Morphol Embryol. 61 (4): 1007–1022. doi:10.47162/RJME.61.4.03. PMC 8343601. PMID 34171050.

ncbi.nlm.nih.gov

Chang C, Ramphul K (2020). "Amantadine". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29763128. Retrieved 2 November 2020.
Danysz W, Dekundy A, Scheschonka A, Riederer P (February 2021). "Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials". J Neural Transm (Vienna). 128 (2): 127–169. doi:10.1007/s00702-021-02306-2. PMC 7901515. PMID 33624170.
Balgi AD, Wang J, Cheng DY, Ma C, Pfeifer TA, Shimizu Y, et al. (1 February 2013). Bouvier NM (ed.). "Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay". PLOS ONE. 8 (2): e55271. Bibcode:2013PLoSO...855271B. doi:10.1371/journal.pone.0055271. PMC 3562233. PMID 23383318.
Hauser RA, Lytle J, Formella AE, Tanner CM (March 2022). "Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease". npj Parkinson's Disease. 8 (1): 29. doi:10.1038/s41531-022-00291-1. PMC 8933492. PMID 35304480.
Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R (2018). "Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials". Braz J Psychiatry. 40 (4): 449–458. doi:10.1590/1516-4446-2017-2393. PMC 6899375. PMID 29898194.
Crosby NJ, Deane KH, Clarke CE, et al. (Cochrane Movement Disorders Group) (22 April 2003). "Amantadine for dyskinesia in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2010 (2): CD003467. doi:10.1002/14651858.CD003467. PMC 8715285. PMID 12804468.
Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ, et al. (Cochrane Acute Respiratory Infections Group) (November 2014). "Amantadine and rimantadine for influenza A in children and the elderly". The Cochrane Database of Systematic Reviews. 2014 (11): CD002745. doi:10.1002/14651858.CD002745.pub4. PMC 7093890. PMID 25415374.
Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C, et al. (Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group) (January 2007). "Amantadine for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2007 (1): CD002818. doi:10.1002/14651858.CD002818.pub2. PMC 6991937. PMID 17253480.
Payne C, Wiffen PJ, Martin S (April 2017). "WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness". The Cochrane Database of Systematic Reviews. 4 (4). Chichester, UK: John Wiley & Sons, Ltd: CD008427. doi:10.1002/14651858.cd008427. PMC 6478103. PMID 28387447.
Generali JA, Cada DJ (September 2014). "Amantadine: multiple sclerosis-related fatigue". Hospital Pharmacy. 49 (8): 710–2. doi:10.1310/hpj4908-710. PMC 4252198. PMID 25477595.
Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. (September 2018). "Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research". Neurology. 91 (10): 450–460. doi:10.1212/WNL.0000000000005926. PMC 6139814. PMID 30089618.
Kafi H, Salamzadeh J, Beladimoghadam N, Sistanizad M, Kouchek M (2014). "Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke". Iranian Journal of Pharmaceutical Research. 13 (2): 591–8. PMC 4157035. PMID 25237355.
Hosenbocus S, Chahal R (February 2013). "Amantadine: a review of use in child and adolescent psychiatry". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 22 (1): 55–60. PMC 3565716. PMID 23390434.
Vollum DI, Parkes JD, Doyle D (June 1971). "Livedo reticularis during amantadine treatment". British Medical Journal. 2 (5762): 627–8. doi:10.1136/bmj.2.5762.627. PMC 1796527. PMID 5580722.
Tarsy D, Parkes JD, Marsden CD (April 1975). "Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias". Journal of Neurology, Neurosurgery, and Psychiatry. 38 (4): 331–335. doi:10.1136/jnnp.38.4.331. PMC 491929. PMID 1095689.
"Amantadine – MeSH". NCBI.
Blanpied TA, Clarke RJ, Johnson JW (March 2005). "Amantadine inhibits NMDA receptors by accelerating channel closure during channel block". The Journal of Neuroscience. 25 (13): 3312–22. doi:10.1523/JNEUROSCI.4262-04.2005. PMC 6724906. PMID 15800186.
Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I (December 1999). "(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain". Br J Pharmacol. 128 (8): 1723–1732. doi:10.1038/sj.bjp.0702995. PMC 1571822. PMID 10588928.
Thomaston JL, Alfonso-Prieto M, Woldeyes RA, Fraser JS, Klein ML, Fiorin G, et al. (November 2015). "High-resolution structures of the M2 channel from influenza A virus reveal dynamic pathways for proton stabilization and transduction". Proceedings of the National Academy of Sciences of the United States of America. 112 (46): 14260–5. Bibcode:2015PNAS..11214260T. doi:10.1073/pnas.1518493112. PMC 4655559. PMID 26578770.
Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M (20 April 2017). "Drug resistance in influenza A virus: the epidemiology and management". Infection and Drug Resistance. 10: 121–134. doi:10.2147/idr.s105473. PMC 5404498. PMID 28458567.
Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA, Sanicas M (April 2018). "The emerging influenza virus threat: status and new prospects for its therapy and control". Archives of Virology. 163 (4): 831–844. doi:10.1007/s00705-018-3708-y. PMC 7087104. PMID 29322273.
Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S (July 2022). "Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials". Iran J Psychiatry. 17 (3): 320–340. doi:10.18502/ijps.v17i3.9733. PMC 9699814. PMID 36474699.
Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA (September 2021). "Amantadine for the treatment of childhood and adolescent psychiatric symptoms". Proceedings. 34 (5): 566–570. doi:10.1080/08998280.2021.1925827. PMC 8366930. PMID 34456474.
Marinescu I, Marinescu D, Mogoantă L, Efrem IC, Stovicek PO (2020). "SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine". Rom J Morphol Embryol. 61 (4): 1007–1022. doi:10.47162/RJME.61.4.03. PMC 8343601. PMID 34171050.

dailymed.nlm.nih.gov

"Gocovri- amantadine capsule, coated pellets". DailyMed. 26 December 2019. Retrieved 22 January 2020.
"Gocovri- amantadine capsule, coated pellets". DailyMed. 26 December 2019. Retrieved 22 January 2020.

pubchem.ncbi.nlm.nih.gov

"Amantadine". PubChem. U.S. Library of Medicine. Retrieved 29 July 2019.

nytimes.com

query.nytimes.com

"Sales of flu drug by du Pont unit a 'disappointment'". The New York Times. Wilmington, Delaware. 5 October 1982. Retrieved 19 May 2008.

semanticscholar.org

api.semanticscholar.org

Hubsher G, Haider M, Okun MS (April 2012). "Amantadine: the journey from fighting flu to treating Parkinson disease". Neurology. 78 (14): 1096–9. doi:10.1212/WNL.0b013e31824e8f0d. PMID 22474298. S2CID 21515610.
Rascol O, Fabbri M, Poewe W (December 2021). "Amantadine in the treatment of Parkinson's disease and other movement disorders". The Lancet. Neurology. 20 (12): 1048–1056. doi:10.1016/s1474-4422(21)00249-0. PMID 34678171. S2CID 239031883.
Henze T, Rieckmann P, Toyka KV (2006). "Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society". European Neurology. 56 (2): 78–105. doi:10.1159/000095699. PMID 16966832. S2CID 5069086.
Ma HM, Zafonte RD (February 2020). "Amantadine and memantine: a comprehensive review for acquired brain injury". Brain Injury. 34 (3): 299–315. doi:10.1080/02699052.2020.1723697. PMID 32078407. S2CID 211232548.
Gao Y, Ma L, Liang F, Zhang Y, Yang L, Liu X, et al. (July 2020). "The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage". Brain Injury. 34 (8): 1084–1088. doi:10.1080/02699052.2020.1780315. PMID 32552090. S2CID 219909194.
Bahrani E, Nunneley CE, Hsu S, Kass JS (March 2016). "Cutaneous Adverse Effects of Neurologic Medications". CNS Drugs. 30 (3): 245–67. doi:10.1007/s40263-016-0318-7. PMID 26914914. S2CID 10560952.
Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (April 2004). "Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine". The European Journal of Neuroscience. 19 (8): 2212–20. doi:10.1111/j.0953-816X.2004.03297.x. PMID 15090047. S2CID 19479968.
Deleu D, Northway MG, Hanssens Y (2002). "Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease". Clinical Pharmacokinetics. 41 (4): 261–309. doi:10.2165/00003088-200241040-00003. PMID 11978145. S2CID 39359348.
Aoki FY, Boivin G, Roberts N (2007). "Influenza virus susceptibility and resistance to oseltamivir". Antiviral Therapy. 12 (4 Pt B): 603–16. doi:10.1177/135965350701200S04.1. PMID 17944268. S2CID 25907483.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S (November 2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology. 25 (7–8): 560–565. doi:10.1002/hup.1154. PMID 21312290. S2CID 30677758.

springer.com

link.springer.com

Bahrani E, Nunneley CE, Hsu S, Kass JS (March 2016). "Cutaneous Adverse Effects of Neurologic Medications". CNS Drugs. 30 (3): 245–67. doi:10.1007/s40263-016-0318-7. PMID 26914914. S2CID 10560952.

symmetrel.com

"Symmetrel (Amantadine) Prescribing Information" (PDF). Endo Pharmaceuticals. May 2003. Archived from the original (PDF) on 17 November 2014. Retrieved 2 August 2007.

tga.gov.au

ebs.tga.gov.au

"Symmetrel (amantadine hydrochloride)" (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Limited. 29 June 2011. Retrieved 24 February 2014.

washingtonpost.com

Sipress A (18 June 2005). "Bird Flu Drug Rendered Useless". The Washington Post. Retrieved 2 August 2007.

web.archive.org

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
"Trilasym 50 mg/ 5 ml Oral Solution – Summary of Product Characteristics (SmPC)". (emc). 24 September 2019. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
"Summary of influenza antiviral susceptibility surveillance findings". World Health Organization (WHO). September 2010 – March 2011. Archived from the original on 27 July 2017. Retrieved 19 July 2019.
"Symmetrel (Amantadine) Prescribing Information" (PDF). Endo Pharmaceuticals. May 2003. Archived from the original (PDF) on 17 November 2014. Retrieved 2 August 2007.
"Enforcement Report – Week of September 23, 2015". U.S. Food and Drug Administration (FDA). Archived from the original on 2 October 2015. Retrieved 30 September 2015.

who.int

"Summary of influenza antiviral susceptibility surveillance findings". World Health Organization (WHO). September 2010 – March 2011. Archived from the original on 27 July 2017. Retrieved 19 July 2019.

worldcat.org

search.worldcat.org

Golan DE, Armstrong EJ, Armstrong AW (2017). Principles of pharmacology: the pathophysiologic basis of drug therapy (4th ed.). Philadelphia: Wolters Kluwer. pp. 142, 199, 205t, 224t, 608, 698–700. ISBN 9781451191004. OCLC 914593652.